Interestingly, in UCP1 knockout mice, FGF19 treatment still appears to have anti-obesity action and increase fecal energy content, which is attributed to the inhibition of the key enzyme CYP7A1 associated with bile acid synthesis, thus reducing the lipid uptake in gut 127. This evidence concerns the gene FGF19 and obesity due to melanocortin 4 receptor deficiency.